Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravitreal RO7200220 for uveitic macular edema
MOH_2023-03-13_012421Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vamikibart in noninfectious uveitis (NIU) and macular edema (3 arms), sponsored by Roche. Primary endpoint: Primary endpoint not reported. Started Mar 2023; status: completed.
02
Drugs
vamikibart
03
Conditions
noninfectious uveitis (NIU)macular edema
Beyond the preview
Go deeper on MOH_2023-03-13_012421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-13_012421.